Editorial commentary: Weight loss for cardiovascular disease prevention – is semaglutide the answer?
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference20 articles.
1. Prevalence of obesity and severe obesity among adults: United States, 2017e2018;Hales,2020
2. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide;Sanchis-Gomar;Mayo Clin Proc,2020
3. Healthy weight and obesity prevention: JACC health promotion series;Lavie;J Am Coll Cardiol,2018
4. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity;Khan;JAMA Cardiol,2018
5. The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent;Iliodromiti;Eur Heart J,2018
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Healthy Lifestyle and Cardiac Rehabilitation for Weight Loss;Current Cardiology Reports;2024-09-04
2. Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?;AIDS;2024-02-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3